These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32798457)

  • 1. Leishmaniasis: An Unforgettable Disease.
    Carranza A; Polanco Garcia M
    Am J Med; 2020 Nov; 133(11):e678. PubMed ID: 32798457
    [No Abstract]   [Full Text] [Related]  

  • 2. Simultaneous occurrence of cutaneous and mucocutaneous leishmaniasis caused by different genotypes of Leishmania (Viannia) braziliensis.
    Hoyos CL; Quipildor M; Bracamonte E; Lauthier JJ; Cajal P; Uncos A; Korenaga M; Hashiguchi Y; Barroso PA; Marco JD
    J Dermatol; 2019 Sep; 46(9):e320-e322. PubMed ID: 30938461
    [No Abstract]   [Full Text] [Related]  

  • 3. [Erysipeloid cutaneous leishmaniasis: about a clinical observation].
    El kartouti A; Elbenaye J; Miloudi M
    Pan Afr Med J; 2015; 21():54. PubMed ID: 26405490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Old-world leishmaniasis of the auricle.
    Skevas A; Kastanioudakis I; Bai M; Kostoula A
    Lancet; 1997 Jan; 349(9044):28-9. PubMed ID: 8988123
    [No Abstract]   [Full Text] [Related]  

  • 5. Disseminated cutaneous leishmaniasis: a patient with 749 lesions.
    Sousa AQ; Pompeu MM; Sólon FR; Frutuoso MS; Teixeira MJ; Silva TM
    Braz J Infect Dis; 2006 Jun; 10(3):230. PubMed ID: 17568857
    [No Abstract]   [Full Text] [Related]  

  • 6. Localized leishmaniasis treated with intralesional meglumine antimoniate.
    Villela-Segura U; Proy-Trujillo H; Ilizaliturri-Flores I; Leal-Ascencio VJ; Eljure-López N
    J Dtsch Dermatol Ges; 2020 Sep; 18(9):1025-1027. PubMed ID: 32656933
    [No Abstract]   [Full Text] [Related]  

  • 7. Unusual manifestation of genital cutaneous leishmaniasis in an immunocompetent patient from São Paulo, Brazil: A case report.
    Reis LC; Lindoso JAL; Celeste BJ; Braz LMA; Ramos-Sanchez EM; Yamashiro-Kanashiro EH; Goto H; Oyafuso LKM
    Rev Soc Bras Med Trop; 2021; 54():e0514-2020. PubMed ID: 33759920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leishmaniasis of the lip.
    Veraldi S; Rigoni C; Gianotti R
    Acta Derm Venereol; 2002; 82(6):469-70. PubMed ID: 12575860
    [No Abstract]   [Full Text] [Related]  

  • 9. Intralesional Antimonial Drug Treatment for Leishmania braziliensis Cutaneous Leishmaniasis: The Knowns and the Unknowns.
    Aronson NE; Billick K
    Clin Infect Dis; 2023 Aug; 77(4):583-588. PubMed ID: 37185765
    [No Abstract]   [Full Text] [Related]  

  • 10. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial.
    Machado PRL; Ribeiro CS; França-Costa J; Dourado MEF; Trinconi CT; Yokoyama-Yasunaka JKU; Malta-Santos H; Borges VM; Carvalho EM; Uliana SRB
    Trop Med Int Health; 2018 Sep; 23(9):936-942. PubMed ID: 29924907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate.
    Senchyna A; Simon S; Cissé H; Ginouves M; Prevot G; Alcoba G; Demar M; Couppie P; Blaizot R
    Br J Dermatol; 2020 Aug; 183(2):389-391. PubMed ID: 32078162
    [No Abstract]   [Full Text] [Related]  

  • 12. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis.
    Mujtaba G; Khalid M
    Int J Dermatol; 1999 Aug; 38(8):607-9. PubMed ID: 10487452
    [No Abstract]   [Full Text] [Related]  

  • 13. What is your diagnosis? Cutaneous leishmaniasis.
    Peine SD; Bryan MG
    Cutis; 2004 Nov; 74(5):284, 287-8. PubMed ID: 15605963
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous lupoid leishmaniasis: a case report.
    Ferahbaş A; Mistik S; Utaş S; Yaman O; Canoz O; Doganay M; Aşçioglu O
    Cutis; 2006 Jan; 77(1):25-8; quiz 37-8. PubMed ID: 16475491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meglumine antimoniate-induced DRESS: original case with a positive skin test.
    Chaabane A; Romdhane HB; Brahim HB; Fredj NB; Chadli Z; Boughattas NA; Chakroun M; Aouam K
    Acta Parasitol; 2018 Dec; 63(4):845-847. PubMed ID: 30367758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory effects of topical diphencyprone for the treatment of acute urban cutaneous leishmaniasis.
    Nahidi Y; Mashayekhi Goyonlo V; Layegh P; Taghavi F; Najaf Najafi M
    J Dermatolog Treat; 2021 Mar; 32(2):220-226. PubMed ID: 31294619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unusual association of American cutaneous leishmaniasis and acquired immunodeficiency syndrome.
    Nogueira-Castañon MC; Pereira CA; Furtado T
    Int J Dermatol; 1996 Apr; 35(4):295-7. PubMed ID: 8786193
    [No Abstract]   [Full Text] [Related]  

  • 18. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
    Moosavian SA; Fallah M; Jaafari MR
    Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
    Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
    Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic meglumine antimoniate-induced severe dilated cardiomyopathy.
    Salah NB; Aounallah A; Manaa L; Lahouel M; Mkhinini H; Belajouza C; Denguezli M
    Dermatol Ther; 2022 Dec; 35(12):e15896. PubMed ID: 36193752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.